As part of our ongoing aim to bring you reports of interesting new studies, we have added a review of 24-week efficacy and safety results from the IXORA-R trial featuring Ixekizumab vs guselkumab for moderate-to-severe plaque psoriasis.
Independent expert commentary is provided by Dr Diana Rubel, a consultant dermatologist in private practice at Woden Dermatology, Canberra.
Please login below to download this issue (PDF)